Cargando…

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway

Previous studies showed that CXCR7 expression was upregulated after enzalutamide (ENZ) treatment, and an increased level of CXCR7 could increase the invasion, migration, and angiogenesis of castration-resistant prostate cancer (CRPC) cells. This study demonstrated that the levels of p-JAK2, p-STAT1,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yong, Yang, Xiaobing, Basourakos, Spyridon P., Zuo, Xuemei, Wei, Dechao, Zhao, Jiahui, Li, Mingchuan, Li, Qiankun, Feng, Tao, Guo, Pengju, Jiang, Yongguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570343/ https://www.ncbi.nlm.nih.gov/pubmed/34746227 http://dx.doi.org/10.3389/fmolb.2021.652443

Ejemplares similares

Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients
por: Luo, Yong, et al.
Publicado: (2021)

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2023)

Proteomimetics of Natural Regulators of JAK–STAT Pathway: Novel Therapeutic Perspectives
por: La Manna, Sara, et al.
Publicado: (2022)

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
por: Luo, Yong, et al.
Publicado: (2018)

RAC3 Promotes Proliferation, Migration and Invasion via PYCR1/JAK/STAT Signaling in Bladder Cancer
por: Cheng, Chuanyu, et al.
Publicado: (2020)

Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer
por: Feng, Tao, et al.
Publicado: (2021)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration
por: Xue, Yishu, et al.
Publicado: (2021)

Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
por: Chen, Xiaoliang, et al.
Publicado: (2020)

Targeting hedgehog-driven mechanisms of drug-resistant cancers
por: Miller, Jade S., et al.
Publicado: (2023)

β-catenin nuclear translocation induced by HIF-1α overexpression leads to the radioresistance of prostate cancer
por: Luo, Yong, et al.
Publicado: (2018)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
por: Greasley, Rosa, et al.
Publicado: (2015)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Paving the way for precise diagnostics of antimicrobial resistant bacteria
por: Wang, Hao, et al.
Publicado: (2022)

The Effectiveness of Wogonin on Treating Cough Mice With Mycoplasma Pneumoniae Infection
por: Liang, Mingchuan, et al.
Publicado: (2022)

Oncological Outcomes of Patients With Different Pathological Features of pT3a Renal Tumor: A Systematic Review and Quantitative Synthesis
por: Guo, Pengju, et al.
Publicado: (2021)

Extracellular vesicles regulate the transmission of insulin resistance and redefine noncommunicable diseases
por: Li, Biao, et al.
Publicado: (2023)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

RIPK4 Suppresses the Invasion and Metastasis of Hepatocellular Carcinoma by Inhibiting the Phosphorylation of STAT3
por: Li, Haoran, et al.
Publicado: (2021)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
por: Luo, Mayao, et al.
Publicado: (2022)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016)

Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer
por: Li, Kai, et al.
Publicado: (2022)

The Role of Tumour Metabolism in Cisplatin Resistance
por: Wang, Lude, et al.
Publicado: (2021)

Theoretical Exploring Selective-Binding Mechanisms of JAK3 by 3D-QSAR, Molecular Dynamics Simulation and Free Energy Calculation
por: Zhu, Jingyu, et al.
Publicado: (2020)

Identification of Tamoxifen-Resistant Breast Cancer Cell Lines and Drug Response Signature
por: Guan, Qingzhou, et al.
Publicado: (2020)

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
por: Xu, Wen, et al.
Publicado: (2023)

Cancer organoid applications to investigate chemotherapy resistance
por: Harada, Kenji, et al.
Publicado: (2022)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

MicroRNA-653-5p Promotes Gastric Cancer Proliferation and Metastasis by Targeting the SOCS6-STAT3 Pathway
por: Li, Zengliang, et al.
Publicado: (2021)

Investigation on acquired palbociclib resistance by LC-MS based multi-omics analysis
por: Xue, Zhichao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gdlq22qhcjbt3anet4q2bc5a4a